The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

FDA Commissioner Marty Makary said his agency plans to release a new framework for vaccine approvals in “coming days.” ...

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

Researchers found people given a shingles vaccine had a 23% lower risk of cardiovascular events, including stroke, heart ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

A virologist, he was director of the Centers for Disease Control and Prevention during the first ... Worse, its school closure guidance and COVID-19 vaccine recommendations (especially for ...

Federal 2025 general recommendations are that children receive about 19 vaccinations and other immunizations. Total doses ...

Domestic and global cases have been reported to the Vaccine Adverse Event Reporting System, run by the FDA and the Centers for Disease Control and Prevention to flag potential safety problems with ...